Autologous conditioning diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA) overview |
High |
August 2023 |
Diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA) induction MATRix (methotrexate cytarabine thiotepa and rituximab) - part 1 |
High |
August 2023 |
Diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA) induction RICE (rituximab ifosfamide carboplatin and etoposide) - part 2 |
High |
August 2023 |
Autologous conditioning diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA) carmustine and thiotepa - part 3 |
High |
August 2023 |
Autologous conditioning protocol BEAM (carmustine etoposide cytarabine melphalan) SAHCDC approved variation to melphalan expiry time based SA Pharmacy advice - infusion to be completed no later than 90 minutes after reconstitution |
High |
August 2022 |
Autologous conditioning protocol busulfan and melphalan SAHCDC approved variation to melphalan expiry time based SA Pharmacy advice - infusion to be completed no later than 90 minutes after reconstitution |
High |
August 2024 |
Autologous conditioning protocol germ cell tumour TICE treatment overview |
High |
August 2022 |
Autologous conditioning protocol germ cell tumour TICE (cARBOplatin and Etoposide) (part 2) |
High |
August 2022 |
Autologous conditioning protocol germ cell tumour TICE (PACLItaxel and IFOSFamide) (part 1) |
High |
August 2022 |
Autologous conditioning protocol high dose melphalan 140 mg/m2 SAHCDC approved variation to melphalan expiry time based SA Pharmacy advice - infusion to be completed no later than 90 minutes after reconstitution
|
High |
August 2022 |
Autologous conditioning protocol high dose melphalan 200 mg/m2 SAHCDC approved variation to melphalan expiry time based SA Pharmacy advice - infusion to be completed no later than 90 minutes after reconstitution |
High |
August 2026 |
Autologous conditioning protocol primary CNS lymphoma carmustine and thiotepa |
High |
August 2024 |
Autologous conditioning relapsed CNS lymphoma overview |
High |
August 2024 |
Relapsed CNS lymphoma induction iFOSFamide liposomal cytarabine methotrexate - part 1 |
High |
August 2024 |
Relapsed CNS lymphoma induction cytarabine liposomal cytarabine thiotepa - part 2(a) |
High |
August 2024 |
Relapsed CNS lymphoma induction cytarabine liposomal cytarabine thiotepa - part 2(b) |
High |
August 2024 |
Autologous conditioning relapsed CNS lymphoma carmustine etoposide thiotepa - part 3 |
High |
August 2024 |